Literature DB >> 5343436

Fluid phase destruction of C2hu by C1hu. II. Unmasking by C4ihu of C1hu specificity for C2hu.

I Gigli, K F Austen.   

Abstract

It has been demonstrated that C1 isolated in the unactivated form fails to inactivate C4 or C2 in the fluid phase, while the activated molecule, C1 rapidly converts C4 to hemolytically inactive C4i, but does not efficiently inactivate C2. The production and presence of C4i now confers on C1 the ability to rapidly inactivate C2. After heating at 56 degrees C, so as to destroy the hemolytic activity, heat inactivated C1 is still capable of inactivating C4 but the presence of C4i no longer confers an ability to inactivate C2. Studies with the subunits of C1-C1q, C1r, C1s, indicate that the action of C1s on C2 can be inhibited by C1r and that this inhibition is reversed by the presence of homologous C4. These studies indicate that the interaction of C4i with a heat labile receptor conformation in C1 uncovers a masked specificity for C2.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5343436      PMCID: PMC2138730          DOI: 10.1084/jem.130.4.833

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

2.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

3.  The relationship of the hemolytic activity of active C'1s to its TAMe esterase action: a new method of purification and assay.

Authors:  K Nagaki; R M Stroud
Journal:  J Immunol       Date:  1969-02       Impact factor: 5.422

4.  Ultracentrifugation of the first component of complement: effects of ionic strength.

Authors:  H R Colten; T Borsos; H J Rapp
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

5.  The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

Authors:  I Gigli; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

6.  Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1965-09       Impact factor: 5.422

7.  Activation of C'1 to C'1 esterase on gel filtration on Sephadex G-200. Studies on normal human serum, euglobulin and hereditary angioneurotic edema serum.

Authors:  A B Laurell; R Siboo
Journal:  Acta Pathol Microbiol Scand       Date:  1966

8.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

9.  The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase.

Authors:  M J Polley; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-09-01       Impact factor: 14.307

10.  The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r.

Authors:  G B Naff; O S Ratnoff
Journal:  J Exp Med       Date:  1968-10-01       Impact factor: 14.307

View more
  9 in total

1.  C1r, subunit of the first complement component: purification, properties, and assay based on its linking role.

Authors:  M M De Bracco; R M Stroud
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

2.  Fluid phase destruction of C2 hu by C1 hu. 3. Changes in activity for synthetic substrates upon cell binding, heat inactivation and interaction with C1INH.

Authors:  M Kondo; I Gigli; K F Austen
Journal:  Immunology       Date:  1972-03       Impact factor: 7.397

3.  Studies on the nature of heat-labile anti-complementary activity in normal human serum.

Authors:  R D Soltis; D Hasz; M J Morris; I D Wilson
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

4.  The human complement system: assembly of the classical pathway C3 convertase.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1980-07-01       Impact factor: 3.857

5.  [C1-inactivator from guinea pig serum-mechanism of action. I. Effect of the inactivator on C1 in free solution].

Authors:  M Loos; W Opferkuch; H Wagner
Journal:  Z Med Mikrobiol Immunol       Date:  1971

6.  Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.

Authors:  R M Des Prez; C S Bryan; J Hawiger; D G Colley
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

Review 7.  The first component of human complement (C1): activation and control.

Authors:  R J Ziccardi
Journal:  Springer Semin Immunopathol       Date:  1983

8.  Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement.

Authors:  I Gigli; A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-12-01       Impact factor: 14.307

9.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.